Otenaproxesul
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2014 (NCT03220633)
Timeline
Indications
Mechanism of action
- Cyclooxygenase-1INHIBITOR
PTGS1 inhibitor
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2cc(C(C)C(=O)Oc3ccc(C(N)=S)cc3)ccc2c1- Mol. weight
- 365.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4211107 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03978208 | Phase 2 | Mar 29, 2019 | Antibe Therapeutics, Veristat, Inc. |
| NCT03291418 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2017 | Antibe Therapeutics, Topstone Research, Toronto, Canada |
| NCT03220633 | Phase 1 | Jun 30, 2014 | Algorithme Pharma Inc, Antibe Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antibe Therapeutics | For profit | 3 | 3 | 2 | 2014 |
| Algorithme Pharma Inc | For profit | 1 | 0 | 1 | 2014 |
| Topstone Research, Toronto, Canada | For profit | 1 | 0 | 1 | 2017 |
| Veristat, Inc. | For profit | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1